Table 1 Characteristics of subjects (n = 154) and glaucoma drug trials (n = 168)

Male sex

68

44%

Black race (n = 142)

111

78%

Trial of:

   Latanoprost

86

51%

   Timolol only

33

20%

   Dorzolamide only

24

14%

   Timolol/dorzolamide combination

1

1%

   Brimonidine

17

10%

   Bimatoprost

6

4%

   Pilocarpine

1

1%

Age (years)

62.7

(11.8)

Baseline IOP, eye 1* (mmHg)

20.2

(5.3)

Baseline IOP, eye 2* (mmHg)

18.3

(5.2)

Uniocular trial IOP, eye 1 (mmHg)

15.3

(4.0)

Uniocular trial IOP, eye 2 (mmHg)

17.4

(5.6)

Followup IOP, mean, eye 1 (mmHg)

16.1

(3.4)

Followup IOP, mean, eye 2 (mmHg)

16.3

(4.5)